

Title: Risk factors for illness severity among pregnant women with confirmed SARS-CoV-2 infection – Surveillance for Emerging Threats to Mothers and Babies Network, 20 state, local, and territorial health departments, March 29, 2020 -January 8, 2021

Authors: Romeo R. Galang, CDC COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA; Suzanne M. Newton, CDC COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA; Kate R. Woodworth, CDC COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA; Isabel Griffin, CDC COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA; Titilope Oduyebo, CDC COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA; Christina L. Sancken, CDC COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA; Emily O'Malley Olsen, CDC COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA; Kathy Aveni, Division of Family Health Services, New Jersey Department of Health, Trenton, New Jersey, USA; Heather Wingate, Communicable and Environmental Disease and Emergency Preparedness, Tennessee Department of Health, Nashville, Tennessee, USA; Hanna Shephard, Bureau of Family Health and Nutrition, Massachusetts Department of Public Health, Boston, Massachusetts, USA; Chris Fussman, Maternal and Child Health Epidemiology Section, Michigan Department of Health and Human Services, Lansing, Michigan, USA; Zahra S. Alaali, Division of Epidemiology, New York State Department of Health, Albany, New York, USA; Samantha Siebman, Emerging Infections Program, Minnesota Department of Health, St. Paul, Minnesota, USA; Umme-Aiman Halai, Acute Communicable Disease Control Program, Los Angeles County Department of Public Health, Los Angeles, California, USA; Camille Delgado Lopez, Division of Children with Special Medical Needs, Puerto Rico Department of Health, San Juan, Puerto Rico, Puerto Rico; Jerusha Barton, Epidemiology Division, Georgia Department of Public Health, Atlanta, GA, USA; Mamie Lush,

Division of Public Health, Nebraska Department of Health and Human Services, Lincoln, Nebraska, USA; Paul H. Patrick, Perinatal and Reproductive Health Division, Oklahoma State Department of Health, Oklahoma City, Oklahoma, USA; Levi Schlosser, Division of Disease Control, North Dakota Department of Health, Bismarck, North Dakota, USA; Ayomide Sokale, Division of Maternal, Child and Family Health, Philadelphia Department of Public Health, Philadelphia, Pennsylvania, USA; Ifrah Chaudhary, Division of Disease Prevention and Control, Houston Health Department, Houston, Texas, USA; Bethany Reynolds, Bureau of Epidemiology, Pennsylvania Department of Health, Pittsburgh, Pennsylvania, USA; Similoluwa Sowunmi, Center for Family Health, California Department of Public Health, Sacramento, California, USA; Nicole Gaarenstroom, Nevada High Sierra Area Health Education Center, Reno, Nevada, USA; Jennifer S. Read, Infectious Disease Epidemiology, Vermont Department of Health, Burlington, Vermont, USA and Larner College of Medicine, University of Vermont, Burlington, Vermont, USA; Sarah Chicchelly, Infectious Disease Epidemiology and Response, Kansas Department of Health and Environment, Topeka, Kansas, USA; Leah de Wilde, Epidemiology Division, US Virgin Islands Department of Health, Christiansted, St. Croix, United States Virgin Islands; Eduardo Azziz-Baumgartner, CDC COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA; Aron J. Hall, CDC COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA; Van T. Tong, CDC COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA; Sascha Ellington, CDC COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA; Suzanne M. Gilboa, CDC COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA; CDC COVID-19 Response Pregnancy and Infant Linked Outcomes Team

Keywords: SARS-CoV-2, COVID-19, pregnancy, illness severity, risk factors

Running title: Pregnancy COVID-19 severity risk factors

Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC).

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Corresponding author: Romeo R. Galang, MD MPH; U.S. Centers for Disease Control and Prevention; 4770 Buford Highway NE, Mailstop S 107-2, Atlanta, GA 30341; eocevent397@cdc.gov; Fax: 404-471-2509; Phone: 404-639-6387

Alternate corresponding author: Sascha Ellington, PhD; U.S. Centers for Disease Control and Prevention; 4770 Buford Highway NE, Mailstop S 107-2, Atlanta, GA 30341; eocevent397@cdc.gov; Fax: 770-471-8650; Phone: 770-488-6037

Word Count: Abstract: 228; **Main Text:** 1,796 of 3000

Summary: Among pregnant women with COVID-19, older age and underlying medical conditions were risk factors for increased illness severity. These findings can be used to inform pregnant women about their risk for severe COVID-19 illness and public health messaging.

Abstract

Background: Pregnant women with coronavirus disease 2019 (COVID-19) are at increased risk for severe illness compared with nonpregnant women. Data to assess risk factors for illness severity among pregnant women with COVID-19 are limited. This study aimed to determine risk factors associated with COVID-19 illness severity among pregnant women with SARS-CoV-2 infection.

Methods: Pregnant women with SARS-CoV-2 infection confirmed by molecular testing were reported during March 29, 2020–January 8, 2021 through the Surveillance for Emerging Threats to Mothers and Babies Network (SET-NET). Criteria for illness severity (asymptomatic, mild, moderate-to-severe, or critical) were adapted from National Institutes of Health and World Health Organization criteria. Crude and adjusted risk ratios for moderate-to-severe or critical COVID-19 illness were calculated for selected demographic and clinical characteristics.

Results: Among 5,963 pregnant women with SARS-CoV-2 infection, moderate-to-severe or critical COVID-19 illness was associated with age 30–39 years, Black/Non-Hispanic race/ethnicity, healthcare occupation, pre-pregnancy obesity, chronic lung disease, chronic hypertension, cardiovascular disease, and pregestational diabetes mellitus. Risk of moderate-to-severe or critical illness increased with the number of underlying medical or pregnancy-related conditions.

Conclusions: Pregnant women with moderate-to-severe or critical COVID-19 illness were more likely to be older and have underlying medical conditions compared to pregnant women with asymptomatic infection or mild COVID-19 illness. This information might help pregnant women understand their risk for moderate-to-severe or critical COVID-19 illness and inform targeted public health messaging.

Introduction

Pregnant women with coronavirus disease 2019 (COVID-19) are at increased risk for severe illness compared with nonpregnant women [1]. A limited number of studies have suggested that risk factors for severe COVID-19 illness, such as older age and underlying medical conditions, might be similar between pregnant and non-pregnant people; however, individual studies have been limited in sample size, varied in sampling frame and inclusion criteria (e.g., inclusion of women with suspected COVID-19 and/or those with confirmed COVID-19), and primarily reported on pregnant women requiring hospitalization (including for childbirth) [2-4]. Additional information on risk factors for severe COVID-19 illness are needed to inform discussions about risk for severe illness, to guide public health messaging and to inform decision-making around resource allocation.

Public health jurisdictions report information, including pregnancy status, on confirmed and probable COVID-19 cases to CDC through the National Notifiable Diseases Surveillance System [5]. Through the Surveillance for Emerging Threats to Mothers and Babies Network (SET-NET), health departments from 20 jurisdictions collected supplementary information on pregnancy outcomes among women with SARS-CoV-2 infection confirmed by nucleic acid amplification testing and reported during March 29, 2020–January 8, 2021 [6]. To determine risk factors associated with COVID-19 illness severity, demographic and selected clinical characteristics were compared between pregnant women with moderate-to-severe or critical illness and those with asymptomatic infection or mild illness.

Materials and Methods

SET-NET is longitudinal surveillance of pregnant women and their infants to understand the effects of emerging and reemerging threats [6]. Supplementary pregnancy-related information is reported for women with laboratory confirmed SARS-CoV-2 infection (based on detection of SARS-CoV-2 in a clinical specimen by nucleic acid amplification testing) during pregnancy through

the day of delivery in 2020 [7]. As of January 8, 2021, health departments from 20 jurisdictions (California [excluding Los Angeles County], Georgia, Houston, Kansas, Los Angeles County, Massachusetts, Michigan, Minnesota, Nebraska, Nevada, New Jersey, New York [excluding New York City], North Dakota, Oklahoma, Pennsylvania [excluding Philadelphia], Philadelphia, Puerto Rico, Tennessee, U.S. Virgin Islands, and Vermont) have contributed data [6]. Pregnancy status was ascertained through routine COVID-19 case surveillance or through matching of reported cases with other data sources (e.g., vital records, administrative data) to identify unreported pregnancy status or verify pregnancy status. Data were abstracted using standard data elements; sources include routine public health investigations, vital records, laboratory reports, and medical records. SET-NET methodology has been previously described [6].

Criteria for illness severity (asymptomatic, mild, moderate-to-severe, or critical) were adapted from National Institutes of Health and World Health Organization severity of illness categories (Figure) [8-9]. Women were considered asymptomatic if reported as having an absence of symptoms using a symptom status variable. Criteria were applied to classify severity using submitted data (including symptoms, intensive care unit (ICU) admission, invasive ventilation, use of COVID-19 therapies, complications associated with COVID-19, and death). If data were not reported for an outcome, the outcome was assumed not to have occurred. Crude risk ratios (RR) for moderate-to-severe or critical illness were calculated for selected demographic characteristics within age group, race/ethnicity, health insurance type, healthcare worker status and selected clinical characteristics, including diagnosis of underlying medical condition (pre-pregnancy obesity [body mass index ≥ 30 kg/m²], chronic lung disease, chronic hypertension, pregestational diabetes mellitus, cardiovascular disease, and immunosuppression), trimester of SARS-CoV-2 infection, and diagnosis of pregnancy-related condition (gestational diabetes and gestational hypertension) as reported through contact tracing, vital statistics, or medical records, compared to selected referent groups [6]. We also

calculated crude risk ratios comparing risk of moderate-to-severe or critical illness among pregnant women with any one condition (underlying medical or pregnancy-related condition), any two conditions, and three or more conditions compared to those without report of any condition. Adjusted risk ratios (aRR) and 95% CIs for moderate-to-severe or critical illness were estimated by binomial regression with the log link function, accounting for age (in years) as a continuous variable. Analyses were conducted using SAS (version 9.4; SAS Institute). This activity was reviewed by CDC, determined to be a non-research, public health surveillance activity, and was conducted consistent with applicable federal law and CDC policy [10].

Results

During March 29–January 8, 2021, data for 10,996 pregnant women with confirmed SARS-CoV-2 infection were submitted to SET-NET. Data for 5,033 (45.8%) women were insufficient for categorizing illness severity. The remainder of this report focuses on 5,963 (54.2%) pregnant women with SARS-CoV-2 infection and sufficient information to categorize illness severity.

Most women were aged 20–39 years (90.8%), 44.9% were Hispanic or Latina (Hispanic) ethnicity, and 55.7% had Medicaid (Table 1). At least one underlying medical condition was reported for 1,827 (35.3%) women, with pre-pregnancy obesity (27.2%) most commonly reported. Gestational diabetes was reported in 8.9% of women and gestational hypertension in 9.0%. Most women had SARS-CoV-2 infection identified in the third (60.6%) or second (29.1%) trimester (based on date of first positive test or symptom onset).

In crude analysis, pregnant women who were 30–34 years (RR=1.35, 95% CI: 1.03, 1.77) and 35–39 years of age (RR=1.44, 95% CI: 1.08, 1.90) were at an increased risk of moderate-to-severe or critical illness compared to pregnant women who were <20 years of age. Pregnant women reported as having a healthcare occupation (RR=1.34, 95% CI: 1.18, 1.53) were at an increased risk of moderate-to-severe or critical illness compared to pregnant women who were not reported as being

in a healthcare occupation. Pregnant women with pre-pregnancy obesity (RR=1.32, 95% CI: 1.17, 1.48), chronic lung disease (RR=1.39, 95% CI: 1.16, 1.66), chronic hypertension (RR=1.37, 95% CI: 1.09, 1.74), cardiovascular disease (RR=1.54, 95% CI: (1.14, 2.08), pregestational diabetes mellitus (RR=1.54, 95% CI: 1.20, 1.98), and gestational diabetes (RR=1.23, 95% CI: 1.04, 1.45) were at increased risk of moderate-to-severe or critical illness compared to pregnant women without these conditions.

Presence of any health condition (underlying medical or pregnancy-related health condition) was associated with 25% increased risk (RR=1.25, 95% CI: 1.12, 1.40), two conditions was associated with a 52% increased risk (RR=1.52, 95% CI: 1.31, 1.78), and three or more conditions was associated with twice the risk (RR=2.13, 95% CI: 1.70, 2.67) of moderate-to-severe or critical illness compared to women without any reported conditions. Age younger than 29 years, age 30 to 39 years, race/ethnicity, health insurance type, trimester of SARS-CoV-2 infection, immunosuppression, and gestational hypertension were not associated with increased risk of moderate-to-severe or critical illness compared to the referent groups.

Adjusted risk ratios were similar to crude risk ratios with two exceptions. After adjustment for age as a continuous variable, Black/Non-Hispanic race/ethnicity was associated with a 22% increased risk (aRR=1.22, 95% CI: 1.04, 1.43) of moderate-to-severe or critical illness compared to the referent group (White, Non-Hispanic race/ethnicity), and gestational diabetes was not found to be associated with increased risk.

Discussion

In an analysis of a large cohort of pregnant women with SARS-CoV-2 infection reported from health departments from 20 jurisdictions through SET-NET, age 30-39 years, Black/Non-Hispanic race/ethnicity, being a healthcare worker, and presence of any underlying medical condition were associated with increased risk of moderate-to-severe or critical illness. The number of underlying

medical or pregnancy-related conditions demonstrated an exposure-response relation with risk for moderate-to-severe or critical illness. Data collection is ongoing, and findings may change as additional data are collected and analyzed. Data are reported by health departments and can be updated as new information becomes available. Enhanced efforts to improve reporting of clinical data related to illness severity are ongoing.

These findings of association between older age, Black/Non-Hispanic race/ethnicity, healthcare occupation, any underlying medical condition and increased risk of moderate-to-severe or critical COVID-19 illness are similar to those observed among nonpregnant adults. There have been few studies focused on risk factors for COVID-19 illness severity in pregnant women; those study findings suggest similar associations with older age and medical comorbidities as seen in the general adult population [2-4]. An association was not found with trimester of SARS-CoV-2 infection, similar to findings from a recent systematic review and meta-analysis of SARS-CoV-2 infection in pregnancy [4]. An association of Hispanic or Latina race/ethnicity with moderate-to-severe or critical illness was not identified; however, Hispanic or Latina women represented half of all women with moderate-to-severe or critical illness in this analysis.

The findings in this report are subject to at least four limitations. First, the clinical criteria for classifying illness severity in this analysis were adapted for surveillance purposes from existing frameworks and used severity indicators that were captured systematically, while other criteria may not have been captured (e.g., respiratory rate and oxygen saturation on room air). Misclassification of illness severity is possible, particularly when data to classify cases into moderate-to-severe or critical illness categories are missing, which might bias towards a lower severity classification and attenuate associations [11]. Similarly, data cannot distinguish between asymptomatic or pre-symptomatic mild infection unless the individual subsequently reported for medical care and information was available in a medical record. Additionally, women who were tested upon hospital

admission for delivery may have developed more severe symptoms later on that were not captured by SET-NET. Among women with date of testing and outcome available, 26% were identified within two days of delivery, which could reflect universal screening on admission. Second, a large portion of women could not be categorized for illness severity due to insufficient information, and testing and reporting might be more frequent among women with more severe illness. The ability to detect differences in demographic characteristics between included and excluded women were limited by a large portion of missing demographic information among excluded cases due to the large surge of cases and limited capacity for complete data collection. Additionally, obtaining accurate data to distinguish underlying medical conditions from pregnancy-related medical conditions (e.g., diabetes vs gestational diabetes) depends on medical record abstraction. Potential misclassification of underlying medical conditions and pregnancy-related medical conditions might limit detection of an association with moderate-to-severe or critical illness. Medical record abstraction of clinical information are ongoing, and statistical comparisons by illness severity should be interpreted with caution. Third, while these data are population-based for the jurisdictions included, they are not nationally representative and include a higher frequency of Hispanic and Latina women compared with all women of reproductive age in national case surveillance data and with provisional national 2020 data on births among women with COVID-19 during pregnancy [1, 12-13]. Fourth, relative to the proportion of women with SARS-CoV-2 infection in the second and third trimesters of pregnancy, few women with first trimester infection have been reported to date. This limits our ability to understand whether trimester of infection is associated with severity of COVID-19 illness.

Despite these limitations, this report has several strengths, including the large size of the population-based cohort, inclusion of both hospitalized and non-hospitalized pregnant women, restriction of the study population to pregnant women with confirmed COVID-19, information to

describe risk factors for illness severity among pregnant women with COVID-19, and uniform application of illness severity criteria.

Future research could further focus on clinical relevance of maternal COVID-19 illness severity and outcomes among newborns, infants, and children. Additional follow-up data on SARS-CoV-2 infection are needed to increase certainty of findings related to severity of COVID-19 illness and timing of infection during pregnancy.

These data can help counsel pregnant women about their risk for moderate-to-severe or critical COVID-19 illness and guide their choice of prevention strategies, target public health messaging, and inform decisions around resource allocation. It is important that pregnant women are informed of their increased risk for severe COVID-19 illness, the signs of severe COVID-19 illness, and strategies for prevention, including vaccination [14-16].

Funding: This study was performed as regular work of the Centers for Disease Control and Prevention. This work is supported by the Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases (ELC) Cooperative Agreement (ELC CK19-1904) and through contractual mechanisms, including the Local Health Department Initiative.

Acknowledgments

Joy Rende, Lindsey Sizemore, Elizabeth Harvey, Nicole D. Longcore, Nadia Thomas, Pauline Santos, Deirdre Depew, Jamie N. Sommer, Claire McGarry, Ona Loper, Shannon Baack, Miguel Valencia Prado, Leishla Nieves Ferrer, Mariam Marcano Huertas, Stephany Perez González, Glorimar Meléndez Rosario, Marangelí Olán Martínez, Hilcon Agosto Rosa, Reynaldo Pérez Alices, J. Michael Bryan, Cristina Meza, Victoria Sanon, Teri Willabus, Cynthia Carpentieri, Michael Andrews, Skip Frick, Robin M. Williams, Samir Koirala, Tyler Faulkner, Shannon Lawrence, Erika Fuchs, Celeste Illian, Elizabeth Wyckoff, Aasta D. Mehta, Patrick Nwachukwu, Lauren Orkis, Richard Olney, Valorie Eckert, Barbara Warmerdam, Olga Barer, State, local, and territorial health

department personnel; U.S. clinical, public health, and emergency response staff members; CDC Epidemiology and Surveillance Task Force, CDC Data Analytics and Modeling Task Force

COVID-19 Pregnancy and Infant Linked Outcomes Team (PILOT)

Jennifer Beauregard, CDC; Jason Hsia, CDC; Kellianne King, CDC; Jean Ko, CDC; Elizabeth Lewis, CDC; Susan Manning, CDC; Varsha Neelam, CDC; Mirna Perez, CDC; Emily Petersen, CDC; Megan Reynolds, CDC; Aspen Riser, CDC; Maria Rivera, CDC; Nicki Roth, CDC; Regina Simeone, CDC; John Sims, CDC; Ashley Smoots, CDC; Margaret Snead, CDC; Penelope Strid, CDC; Diana Valencia, CDC; Bailey Wallace, CDC; Tineka Yowe-Conley, CDC; Laura Zambrano, CDC; Lauren Zapata, CDC; Amanda Akosa, Eagle Global Scientific; John F. Nahabedian III, Eagle Global Scientific; Amitsingh Rathore, Eagle Global Scientific; Neha Shinde, Eagle Global Scientific; Veronica Burkel, Eagle Medical; Dena Cherry, General Dynamics Informational Technology; Daniel Chang, Oak Ridge Institute for Science and Education; Charise Fox, Oak Ridge Institute for Science and Education; Emily Reeves, Oak Ridge Institute for Science and Education; Ayzsa Tannis, Oak Ridge Institute for Science and Education; Susanna Trost, Oak Ridge Institute for Science and Education

Potential conflict of interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed. This work has not been published previously and is not under consideration for publication elsewhere.

References

1. Zambrano LD, Ellington S, Strid P, et al. Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status

- United States, January 22–October 3, 2020. *MMWR Morb Mortal Wkly Rep*, **2020**; 69:1641–1647.
2. Di Martino D, Chiaffarino F, Patanè L, et al. Assessing risk factors for severe forms of COVID-19 in a pregnant population: A clinical series from Lombardy, Italy. *Int J Gynaecol Obstet*. Epub ahead of print. October 24, 2020 [cited 2021 Feb 16] Available from: doi: 10.1002/ijgo.13435.
3. Brandt JS, Hill J, Reddy A, et al. Epidemiology of coronavirus disease 2019 in pregnancy: risk factors and associations with adverse maternal and neonatal outcomes. *Am J Obstet Gynecol*. Epub ahead of print. September 25, 2020 [cited 2021 Feb 16] Available from: doi: 10.1016/j.ajog.2020.09.043.
4. Allotey J, Stallings E, Bonet M, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. *BMJ*, **2020**; 370:m3320.
5. Centers for Disease Control and Prevention – National Center for Immunization and Respiratory Diseases – Information for Health Departments on Reporting Cases of COVID-19. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/php/reporting-pui.html>. Accessed December 21, 2020.
6. Woodworth KR, Reynolds MR, Burkel V, et al. A Preparedness Model for Mother–Baby Linked Longitudinal Surveillance for Emerging Threats. *Matern Child Health J*, **2021** Jan 4:1–9.
7. Centers for Disease Control and Prevention – Office of Public Health Scientific Services – Coronavirus Disease 2019 (COVID-19) 2020 Interim Case Definition, Approved August 5, 2020; Available from: <https://wwwn.cdc.gov/nndss/conditions/coronavirus-disease-2019-covid-19/case-definition/2020/08/05/>. Accessed February 4, 2021.

8. National Institutes of Health – COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Available from: <https://www.covid19treatmentguidelines.nih.gov/>. Accessed December 21, 2020.
9. World Health Organization – Clinical management of COVID-19: interim guidance. Available from: <https://apps.who.int/iris/handle/10665/332196>. Accessed December 21, 2020.
10. Department of Health and Human Services – 45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C. Sect. 241(d); 5 U.S.C. Sect. 552a; 44 U.S.C. Sect. 3501 et seq. Available from: <https://www.hhs.gov/ohrp/sites/default/files/ohrp/policy/ohrpreulations.pdf>. Accessed February 4, 2021.
11. Lipsitch M, Donnelly CA, Fraser C, et al. Potential biases in estimating absolute and relative case-fatality risks during outbreaks. *PLoS Negl Trop Dis*, **2015**; 9:e0003846.
12. Centers for Disease Control and Prevention – National Center for Health Statistics – Maternal and Infant Characteristics Among Women with Confirmed or Presumed Cases of Coronavirus Disease (COVID-19) During Pregnancy. Available from: <https://www.cdc.gov/nchs/covid19/technical-linkage.htm>. Accessed December 21, 2020.
13. Ellington S, Strid P, Tong VT, et al. Characteristics of women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status—United States, January 22–June 7, 2020. *MMWR Morb Mortal Wkly Rep*, **2020**; 69:769–75.
14. Centers for Disease Control and Prevention – National Center for Immunization and Respiratory Diseases – Symptoms of Coronavirus. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html>. Accessed December 21, 2020.

15. Centers for Disease Control and Prevention – National Center for Immunization and Respiratory Diseases – Pregnancy, Breastfeeding, and Caring for Newborns. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/pregnancy-breastfeeding.html/>. Accessed February 8, 2021.
16. Centers for Disease Control and Prevention – National Center for Immunization and Respiratory Diseases – Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States. Available from: https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fcovid-19%2Finfo-by-product%2Fpfizer%2Fclinical-considerations.html. Accessed February 1, 2020.

336 **Figure. Criteria for categorizing severity of illness among pregnant women with SARS-CoV-2**
 337 **infection, Surveillance for Emerging Threats to Mothers and Babies Network (SET-NET)**

Severity of Illness	Description of the surveillance categorization of severity of COVID-19 illness among pregnant women ^a
Critical	Defined as reported with complication of COVID-19: mechanical ventilation/intubation, ECMO, ICU admission, ARDS, respiratory failure, septic shock, or multiple organ dysfunction; COVID-19 listed as a cause of death
Moderate-to-Severe^b	Defined as reported with any of the following, and not meeting criteria for critical illness: <ul style="list-style-type: none"> • Symptoms of dyspnea/shortness of breath AND at least one of the following: fever or cough. • Receipt of oxygen therapy by nasal cannula or a high-flow oxygen device, pneumonia • Treatment for COVID-19 with remdesivir, convalescent plasma, hydroxychloroquine + azithromycin, hydroxychloroquine alone. Additional treatments may be included as evidence of disease severity, referring to NIH treatment guidelines.
Mild^c	Defined as symptomatic illness with at least one of the individual symptoms reported, and not meeting criteria for moderate-to-severe or critical illness □
Asymptomatic infection^d	Defined as reported as asymptomatic ^e (not just absence of reported symptoms) and not meeting criteria for mild, moderate-to-severe, or critical illness
Insufficient information	Defined as missing information needed to categorize into asymptomatic infection, mild, moderate-to-severe, or critical illness

338 Abbreviations: ARDS = acute respiratory distress syndrome, ECMO = extracorporeal membrane

339 oxygenation, ICU= intensive care unit

340 ^aAdapted from National Institutes of Health

341 <https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/> and World Health

342 Organization <https://www.who.int/publications/i/item/clinical-management-of-covid-19>.

343 ^bData considered in classification included systematically collected indicators of illness severity. A search was

344 performed to identify informative clinical data in free text notes; however, free text notes are not routinely

345 collected and are often missing. Ability to distinguish moderate and severe illness is limited by data which are

346 not routinely collected and highly likely to be missing from free text notes: respiratory rate, blood oxygen
347 saturation on room air.

348 ^cLimitations: persons with mild symptoms may not seek medical care. Unless a case interview was performed,
349 we will not have information on mild symptoms.

350 ^dLimitations include inability to distinguish between asymptomatic or pre-symptomatic mild infection unless
351 the individual reported for medical care and information was available in a medical record.

352 ^eResponse options for symptom status include (symptomatic, asymptomatic, and unknown).

353 <https://www.cdc.gov/coronavirus/2019-ncov/downloads/pui-form.pdf>.

354 **Table 1. Risk ratios for moderate-to-severe or critical illness among pregnant women with SARS-CoV-2 infection during**
355 **pregnancy compared to asymptomatic infection or mild illness for selected demographic and clinical characteristics,**
356 **Surveillance for Emerging Threats to Mothers and Babies Network, 20 state, local, and territorial health departments, March 29,**
357 **2020 -January 8, 2021 (n=5,963)^a**

	No. of women (%)			Risk Ratio	95% CI	Adjusted Risk Ratio	95% CI
	[Total no. of women with available information]						
	Total	Moderate-to-severe or critical illness	Asymptomatic infection or mild illness				
Total	5,963	1,379 (23.1)	4,584 (76.9)				
Age	[4215]	[1032]	[3183]				
<20	249 (5.9)	49 (4.8)	200 (6.3)	1	ref.	-	-
20-24	847 (20.1)	182 (17.6)	665 (20.9)	1.09	(0.82, 1.44)	-	-
25-29	1306 (31.0)	307 (29.8)	999 (31.4)	1.19	(0.91, 1.56)	-	-
30-34	1098 (26.1)	292 (28.3)	806 (25.3)	1.35	(1.03, 1.77)	-	-
35-39	577 (13.7)	163 (15.8)	414 (13.0)	1.44	(1.08, 1.90)	-	-
40 +	138 (3.3)	39 (3.8)	99 (3.1)	1.44	(1.00, 2.07)	-	-
Race/ethnicity	[4961]	[1171]	[3790]				
White, Non-Hispanic	1494 (30.1)	340 (29.0)	1154 (30.5)	1	ref.	1	ref.
Asian, Non-Hispanic	178 (3.6)	50 (4.3)	128 (3.4)	1.23	(0.96, 1.59)	1.27	(0.95, 1.68)
Black, Non-Hispanic	898 (18.1)	227 (19.4)	671 (17.7)	1.11	(0.96, 1.29)	1.22	(1.04, 1.43)
Hispanic or Latina	2225 (44.9)	526 (44.9)	1699 (44.8)	1.04	(0.92, 1.17)	0.92	(0.80, 1.05)
Multiple or other, Non-Hispanic	166 (3.4)	28 (2.4)	138 (3.6)	0.74	(0.52, 1.05)	1.02	(0.71, 1.46)
Health insurance	[3735]	[931]	[2804]				
Private	1451 (38.9)	342 (36.7)	1109 (39.6)	1	ref.	1	ref.
Medicaid	2079 (55.7)	545 (58.5)	1534 (54.7)	1.11	(0.99, 1.25)	1.13	(0.99, 1.29)
Other	130 (3.5)	26 (2.8)	104 (3.7)	0.85	(0.59, 1.21)	1.07	(0.75, 1.51)

Self-pay/none	75 (2.0)	18 (1.9)	57 (2.0)	1.02	(0.67, 1.54)	0.95	(0.61, 1.47)
Healthcare occupation	[3245]	[806]	[2439]				
No	2512 (77.4)	579 (71.8)	1933 (79.3)	1	ref.	1	ref.
Yes	733 (22.6)	227 (28.2)	506 (20.8)	1.34	(1.18, 1.53)	1.31	(1.14, 1.50)
Trimester of SARS-CoV-2 infection^c	[5100]	[1216]	[3884]				
First	525 (10.3)	123 (10.1)	402 (10.4)	1	ref.	1	ref.
Second	1486 (29.1)	379 (31.2)	1107 (28.5)	1.09	(0.91, 1.30)	1.01	(0.82, 1.24)
Third	3089 (60.6)	714 (58.7)	2375 (61.2)	1	(0.83, 1.17)	1.02	(0.84, 1.24)
Underlying medical condition^d	[5177]	[1144]	[4033]				
Any underlying medical condition	1827 (35.3)	498 (43.5)	1329 (33.0)	1.41	(1.28, 1.57)	1.48	(1.32, 1.67)
Obesity ^e	1407 (27.2)	373 (32.6)	1034 (25.6)	1.32	(1.17, 1.48)	1.29	(1.12, 1.48)
Chronic lung disease	318 (6.1)	102 (8.9)	216 (5.4)	1.39	(1.16, 1.66)	1.44	(1.19, 1.73)
Chronic hypertension	164 (3.2)	51 (4.5)	113 (2.8)	1.37	(1.09, 1.74)	1.35	(1.05, 1.73)
Diabetes mellitus (type 1 or type 2)	117 (2.3)	41 (3.6)	76 (1.9)	1.54	(1.20, 1.98)	1.57	(1.21, 2.04)
Cardiovascular disease	86 (1.7)	30 (2.6)	56 (1.4)	1.54	(1.14, 2.08)	1.46	(1.06, 2.02)
Immunosuppression	41 (0.8)	11 (1.0)	30 (0.7)	1.28	(0.76, 2.12)	1.49	(0.88, 2.53)
Pregnancy-related condition^d	[4470]	[995]	[3475]				
Gestational diabetes	447 (10.0)	119 (12.0)	328 (9.4)	1.23	(1.04, 1.45)	1.1	(0.90, 1.33)
Gestational hypertension	452 (10.1)	115 (11.6)	337 (9.7)	1.16	(0.98, 1.38)	1.11	(0.92, 1.35)
Number of conditions^f	[5337]	[1166]	[4171]				
None	3106 (58.2)	589 (50.5)	2517 (60.4)	1	ref.	1	ref.
Any 1 condition	1602 (30.0)	381 (32.7)	1221 (29.3)	1.25	(1.12, 1.40)	1.3	(1.13, 1.48)
Any 2 conditions	505 (9.5)	146 (12.5)	359 (8.6)	1.52	(1.31, 1.78)	1.59	(1.33, 1.89)
Any 3 or more conditions	124 (2.3)	50 (4.3)	74 (1.8)	2.13	(1.70, 2.67)	1.82	(1.39, 2.39)

^aDuring March 29, 2020–January 8, 2021, data for 10,996 pregnant women with SARS-CoV-2 infection were submitted to SET-NET. Data for 5,033

(45.8%) women were insufficient for categorizing severity of illness.

^bAdjusted for age as a continuous variable.

^cTrimester of SARS-CoV-2 infection based on date of first positive test or symptom onset.

- 362 ^dReferent group: pregnant women without report of underlying medical condition or pregnancy-related condition, respectively.
- 363 ^ePregestational obesity defined as body mass index ≥ 30 kg/m².
- 364 ^fIncludes underlying medical conditions (pre-pregnancy obesity, chronic lung disease, chronic hypertension, diabetes mellitus (type 1 or type 2),
- 365 cardiovascular disease and immunosuppression) and pregnancy-related conditions (gestational diabetes and gestational hypertension